Last week's blowup of Isis Pharmaceuticals Inc.'s antisense drug, Affinitak, in a Phase III trial for non-small-cell lung cancer placed a question mark above that category of therapeutics, but nobody is flying the white flag of surrender yet. (BioWorld Financial Watch)